Corcept Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 6 Sell calls were followed by roughly flat moves (+1%) three months out.
- Recent price momentum is -31.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 47.8x | Better than 10% |
| Forward P/E | 13.4x | Better than 62% |
| Price / Sales | 8.3x | Better than 13% |
| P/E vs own 5-yr range | 74th pctl | Better than 35% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 23.7% | Better than 86% |
| Net income CAGR (3Y) | -0.6% | Better than 40% |
| Free cash flow CAGR (3Y) | 5.7% | Better than 46% |
Profitability B+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 98.3% | Better than 99% |
| Operating margin | 5.9% | Better than 38% |
| Net margin | 12.9% | Better than 67% |
| Return on equity | 14.8% | Better than 68% |
| Return on invested capital | 12.2% | Better than 76% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -48.0% | Better than 6% |
| 6-month return | 5.6% | Better than 66% |
| 12-month return (ex latest month) | 39.1% | Better than 77% |
| Distance below 52-week high | 49.7% | Better than 19% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.9x | Better than 72% |
| Debt to assets | 0.7% | Better than 94% |
| Interest coverage | 1,078.7x | Better than 98% |
| Free cash flow / net income | 142.3% | Better than 62% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 160.5% | Better than 91% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 64.98
- Open
- 64.07
- Day range
- 62.81 - 65.13
- Avg price
- 63.67
- Volume
- 1.09M
- Turnover
- 69.47M
- Turnover ratei
- 1.12%
- Volume ratioi
- 1.12
- Amplitudei
- 3.57%
- 52-week rangei
- 28.66 - 126.38
Valuation
- P/Ei
- 77.59
- P/E (TTM)i
- 47.83
- P/Bi
- 8.35
- EPSi
- 0.82
- Book value / shi
- 7.62
- Net profit
- 89.74M
- Net assets
- 833.74M
Share structure
- Market cap
- 6.96B
- Float capi
- 6.22B
- Shares out
- 109.44M
- Float sharesi
- 97.83M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
49.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-35.63M net over the window
Short interest
- Shares short
- 9.13M
- % of floati
- 8.44%
- Days to coveri
- 8.10
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Corcept Therapeutics (CORT)?
Corcept Therapeutics last traded at 63.62. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Corcept Therapeutics's market cap?
About 6.96B.
What is the P/E ratio of Corcept Therapeutics?
The trailing twelve-month P/E is 47.83, below its own 5-year average of 58.48 — toward the top of its historical range (73.55% percentile). See the Valuation tab for the full history.
Does Corcept Therapeutics pay a dividend?
Corcept Therapeutics does not currently pay a regular dividend.
Is Corcept Therapeutics a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 165.75, which implies 160.5% upside from the current price. This is not investment advice.
What is Corcept Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Corcept Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Corcept Therapeutics discussion 0 comments